NF-κB signaling, as the matchmaker of cancer and inflammation [10], holds potential for cancer therapeutics, allowing a targeted strategy directed simultaneously toward cancer cells and the cancer associated inflammatory cells. The gene discussed is NFKB1; the disease is cancer.